Location Evansville, Indiana Compounded versions of semaglutide are not FDA-approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy
Weight loss injectables, like any medication, can cause side effects
Synthetic exendin-4 became exenatide, marketed as Byetta, and in 2005, it became the first GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes
August 21, 2025: Novo Nordisk to Pay an Estimated $2 Billion for Ozempic Lawsuits According to a recent analysis, Novo Nordisk may have to pay an estimated $2 billion in compensation for the lawsuits being filed against it
Individuals who develop blood clots are often at risk for developing more despite intervention to remove or resolve the clots